Publicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (7)

2024

  1. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

    Clinical Cancer Research, Vol. 30, Núm. 20, pp. 4609-4617

2022

  1. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor

    European Journal of Cancer, Vol. 174, pp. S116

2020

  1. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895

2019

  1. Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network

    Cancer Research, Vol. 79, Núm. 3, pp. 625-638

2015

  1. Proteasome inhibition enhances the killing effect of BikDD gene therapy

    American Journal of Translational Research, Vol. 7, Núm. 2, pp. 319-327

2014

  1. S6k1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer

    American Journal of Translational Research, Vol. 6, Núm. 4, pp. 361-376

2011

  1. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance

    Clinical Cancer Research, Vol. 17, Núm. 12, pp. 4155-4166